Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 141, Issue 9, pp 1511–1522 | Cite as

Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds

  • Hirota Fujiki
  • Eisaburo Sueoka
  • Tatsuro Watanabe
  • Masami Suganuma
Review - Cancer Research

Abstract

Purpose

In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6 % in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs.

Results and discussion

The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153–DR5–TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3 %. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage.

Conclusion

Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.

Keywords

Apoptosis Cancer stem cells EGCG GADD153 NSAID 

Abbreviations

EGCG

(−)-Epigallocatechin gallate

ER

Estrogen receptor

GADD153

Growth arrest and DNA damage-inducible gene 153

GTE

Green tea extract

HDAC

Histone deacetylase

NSAIDs

Nonsteroidal anti-inflammatory drugs

TRAIL

TNF-related apoptosis-inducing ligand

Notes

Acknowledgments

We thank Drs. Kei Nakachi and Kazue Imai at Department of Radiobiology/Molecular Epidemiology, Radiation Effects Research Foundation, Hiroshima; Drs. Masahito Shimizu and Hisataka Moriwaki at Department of Medicine, Gifu University; and Mrs. Yoshiaki Kitaoka, Kenta Nakajima, and Dr. Atsushi Takahashi at the Green Tea Laboratory of Saitama Prefectural Agriculture and Forestry Research Center, for their fruitful collaborations and stimulating discussion; and Mrs. Ikuko Shiotani at the Saitama Cancer Center Hospital for her generous collaborations.

Conflict of interest

Here, we declare that we have no conflicts of interest.

References

  1. Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5:417–421CrossRefPubMedGoogle Scholar
  2. Adhami VM et al (2007) Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 13:1611–1619CrossRefPubMedGoogle Scholar
  3. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K (2007) Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 6:1006–1012CrossRefPubMedGoogle Scholar
  4. Amin AR et al (2010) Enhanced anti-tumor activity by the combination of the natural compounds (−)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem 285:34557–34565PubMedCentralCrossRefPubMedGoogle Scholar
  5. Bannerman B et al (2011) Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68:1145–1154PubMedCentralCrossRefPubMedGoogle Scholar
  6. Basu A, Haldar S (2009) Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. Int J Oncol 34:281–286PubMedGoogle Scholar
  7. Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO (2013) Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res 319:697–706PubMedCentralCrossRefPubMedGoogle Scholar
  8. Chisholm K, Bray BJ, Rosengren RJ (2004) Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs 15:889–897CrossRefPubMedGoogle Scholar
  9. Choudhury SR, Balasubramanian S, Chew YC, Han B, Marquez VE, Eckert RL (2011) (−)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32:1525–1532PubMedCentralCrossRefPubMedGoogle Scholar
  10. Das A, Banik NL, Ray SK (2009) Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Int J Oncol 34:757–765PubMedCentralPubMedGoogle Scholar
  11. Davenport A, Frezza M, Shen M, Ge Y, Huo C, Chan TH, Dou QP (2010) Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int J Mol Med 25:465–470PubMedCentralPubMedGoogle Scholar
  12. Fujiki H, Suganuma M (2012) Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett 324:119–125CrossRefPubMedGoogle Scholar
  13. Fujiki H et al (2001) Cancer prevention with green tea and monitoring by a new biomarker, hnRNP B1. Mutat Res 480–481:299–304CrossRefPubMedGoogle Scholar
  14. Fujiki H, Suganuma M, Imai K, Nakachi K (2002) Green tea: cancer preventive beverage and/or drug. Cancer Lett 188:9–13CrossRefPubMedGoogle Scholar
  15. Fujiki H, Imai K, Nakachi K, Shimizu M, Moriwaki H, Suganuma M (2012) Challenging the effectiveness of green tea in primary and tertiary cancer prevention. J Cancer Res Clin Oncol 138:1259–1270CrossRefPubMedGoogle Scholar
  16. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD (2009) Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 15:1250–1258PubMedCentralCrossRefPubMedGoogle Scholar
  17. Haque A, Rahman MA, Chen ZG, Shin DM, Amin AR (2014) Combination of erlotinib and epigallocatechin-3-gallate induces apoptosis of squamous cell carcinoma of the head and neck through posttranslational regulation of Bim and Bcl-2. Proc Am Assoc Cancer Res 55:548Google Scholar
  18. Härdtner C, Multhoff G, Falk W, Radons J (2012) (−)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol 684:36–43CrossRefPubMedGoogle Scholar
  19. Hsieh TC, Wu JM (2008) Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int J Oncol 33:851–859PubMedGoogle Scholar
  20. Hsieh TC, Wu JM (2009) Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res 29:4025–4032PubMedCentralPubMedGoogle Scholar
  21. Lee SH, Nam HJ, Kang HJ, Kwon HW, Lim YC (2013) Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur J Cancer 49:3210–3218CrossRefPubMedGoogle Scholar
  22. Li Y, Yuan YY, Meeran SM, Tollefsbol TO (2010) Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol Cancer 9:274PubMedCentralCrossRefPubMedGoogle Scholar
  23. Liang G et al (2010) Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 37:111–123PubMedGoogle Scholar
  24. Masuda M, Suzui M, Weinstein IB (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7:4220–4229PubMedGoogle Scholar
  25. Maytin EV, Ubeda M, Lin JC, Habener JF (2001) Stress-inducible transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via p38 kinase-dependent and -independent mechanisms. Exp Cell Res 267:193–204CrossRefPubMedGoogle Scholar
  26. Mazumder ME, Beale P, Chan C, Yu JQ, Huq F (2012) Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells. Anticancer Res 32:4851–4860PubMedGoogle Scholar
  27. Milligan SA et al (2009) The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 15:4885–4894PubMedCentralCrossRefPubMedGoogle Scholar
  28. Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE (2013) Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS ONE 8:e73464PubMedCentralCrossRefPubMedGoogle Scholar
  29. Mohan N, Karmakar S, Banik NL, Ray SK (2011) SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells. Neurochem Res 36:1383–1396CrossRefPubMedGoogle Scholar
  30. Nair S et al (2008) Synergistic effects of a combination of dietary factors sulforaphane and (−)-epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells. Pharm Res 25:387–399CrossRefPubMedGoogle Scholar
  31. Nair S et al (2010) Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6 J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 31:1223–1240PubMedCentralCrossRefPubMedGoogle Scholar
  32. Nakachi K, Suemasu K, Suga K, Takeo T, Imai K, Higashi Y (1998) Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89:254–261CrossRefPubMedGoogle Scholar
  33. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K (2000) Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors 13:49–54CrossRefPubMedGoogle Scholar
  34. Nihal M, Roelke CT, Wood GS (2010) Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (−)-epigallocatechin-3-gallate (EGCG). Pharm Res 27:1103–1114CrossRefPubMedGoogle Scholar
  35. Okabe S, Fujimoto N, Sueoka N, Suganuma M, Fujiki H (2001) Modulation of gene expression by (−)-epigallocatechin gallate in PC-9 cells using a cDNA expression array. Biol Pharm Bull 24:883–886CrossRefPubMedGoogle Scholar
  36. Saha A, Kuzuhara T, Echigo N, Suganuma M, Fujiki H (2010) New role of (−)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev Res 3:953–962CrossRefGoogle Scholar
  37. Sakata M, Ikeda T, Imoto S, Jinno H, Kitagawa Y (2011) Prevention of mammary carcinogenesis in C3H/OuJ mice by green tea and tamoxifen. Asian Pac J Cancer Prev 12:567–571PubMedGoogle Scholar
  38. Saldanha SN, Kala R, Tollefsbol TO (2014) Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp Cell Res 324:40–53PubMedCentralCrossRefPubMedGoogle Scholar
  39. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ (2008) A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer 99:1056–1063PubMedCentralCrossRefPubMedGoogle Scholar
  40. Shimizu M et al (2008) Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 17:3020–3025CrossRefPubMedGoogle Scholar
  41. Shiraishi T et al (2005) Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res 65:6364–6370CrossRefPubMedGoogle Scholar
  42. Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ (2008) The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int J Cancer 122:1966–1971CrossRefPubMedGoogle Scholar
  43. Stearns ME, Wang M (2011) Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl Oncol 4:147–156PubMedCentralCrossRefPubMedGoogle Scholar
  44. Stearns ME, Amatangelo MD, Varma D, Sell C, Goodyear SM (2010) Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol 177:3169–3179PubMedCentralCrossRefPubMedGoogle Scholar
  45. Stuart EC, Rosengren RJ (2008) The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells. Life Sci 82:943–948CrossRefPubMedGoogle Scholar
  46. Stuart EC, Larsen L, Rosengren RJ (2007) Potential mechanisms for the synergistic cytotoxicity elicited by 4-hydroxytamoxifen and epigallocatechin gallate in MDA-MB-231 cells. Int J Oncol 30:1407–1412PubMedGoogle Scholar
  47. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H (1998) Wide distribution of [3H](−)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 19:1771–1776CrossRefPubMedGoogle Scholar
  48. Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H (1999) Synergistic effects of (−)-epigallocatechin gallate with (−)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res 59:44–47PubMedGoogle Scholar
  49. Suganuma M, Ohkura Y, Okabe S, Fujiki H (2001) Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol 127:69–72CrossRefPubMedGoogle Scholar
  50. Suganuma M, Kurusu M, Suzuki K, Tasaki E, Fujiki H (2006) Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene. Int J Cancer 119:33–40CrossRefPubMedGoogle Scholar
  51. Suganuma M, Saha A, Fujiki H (2011) New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 102:317–323CrossRefPubMedGoogle Scholar
  52. Tan M, Norwood A, May M, Tucci M, Benghuzzi H (2006) Effects of (−)-epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomed Sci Instrum 42:363–371PubMedGoogle Scholar
  53. Tang SN, Singh C, Nall D, Meeker D, Shankar S, Srivastava RK (2010) The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 5:14PubMedCentralCrossRefPubMedGoogle Scholar
  54. Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK (2012) Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer 131:30–40PubMedCentralCrossRefPubMedGoogle Scholar
  55. Wu H, Yokoyama T, Zhu B, Shimoishi Y, Murata Y, Nakamura Y (2008) (−)-Epigallocatechin-3-gallate potentiates the cytotoxicity induced by benzyl isothiocyanate and hydrogen peroxide in human Jurkat T lymphocytes. Biosci Biotechnol Biochem 72:3034–3037CrossRefPubMedGoogle Scholar
  56. Wu H, Xin Y, Xiao Y, Zhao J (2012) Low-dose docetaxel combined with (−)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother Radiopharm 27:204–209CrossRefPubMedGoogle Scholar
  57. Xu F, Zhen YS (2003) (−)-Epigallocatechin-3-gallate enhances anti-tumor effect of cytosine arabinoside on HL-60 cells. Acta Pharmacol Sin 24:163–168PubMedGoogle Scholar
  58. Yang XW et al (2012) Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res 42:494–501CrossRefPubMedGoogle Scholar
  59. Yokoyama M, Noguchi M, Nakao Y, Ysunaga M, Yamasaki F, Iwasaka T (2008) Antiproliferative effects of the major tea polyphenol, (−)-epigallocatechin gallate and retinoic acid in cervical adenocarcinoma. Gynecol Oncol 108:326–331CrossRefPubMedGoogle Scholar
  60. Yoshida N (1992) Cancer cells talked in this way. Bungeishunju, Ltd, Tokyo, p 267 (Japanese)Google Scholar
  61. Yoshida T et al (2005) Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 65:5662–5667CrossRefPubMedGoogle Scholar
  62. Zhang X et al (2008) Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 123:1005–1014PubMedCentralCrossRefPubMedGoogle Scholar
  63. Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q (2013) Combination of low concentration of (−)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int J Mol Sci 14:12023–12036PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Hirota Fujiki
    • 1
  • Eisaburo Sueoka
    • 1
  • Tatsuro Watanabe
    • 1
  • Masami Suganuma
    • 2
  1. 1.Department of Clinical Laboratory Medicine, Faculty of MedicineSaga UniversityNabeshima, SagaJapan
  2. 2.Graduate School of Science and EngineeringSaitama UniversitySakuraku, SaitamaJapan

Personalised recommendations